1.17 USD
-0.03 (-2.5%)
0.67 USD
-0.5 (-42.74%)
Overall BCLI gets a fundamental rating of 1 out of 10. We evaluated BCLI against 525 industry peers in the Biotechnology industry. BCLI may be in some trouble as it scores bad on both profitability and health. BCLI does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- BCLI had negative earnings in the past year.
- BCLI had a negative operating cash flow in the past year.
- BCLI had negative earnings in each of the past 5 years.
- BCLI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- BCLI's Return On Assets of -310.45% is on the low side compared to the rest of the industry. BCLI is outperformed by 92.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -310.45% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-443.44%
ROA(5y)-295.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BCLI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- Compared to 1 year ago, BCLI has more shares outstanding
- The number of shares outstanding for BCLI has been reduced compared to 5 years ago.
- There is no outstanding debt for BCLI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -103.72, we must say that BCLI is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of BCLI (-103.72) is worse than 96.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -103.72 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- BCLI has a Current Ratio of 0.21. This is a bad value and indicates that BCLI is not financially healthy enough and could expect problems in meeting its short term obligations.
- BCLI has a worse Current ratio (0.21) than 94.96% of its industry peers.
- A Quick Ratio of 0.21 indicates that BCLI may have some problems paying its short term obligations.
- The Quick ratio of BCLI (0.21) is worse than 94.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.21 | ||
| Quick Ratio | 0.21 |
3. Growth
3.1 Past
- BCLI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.54%, which is quite impressive.
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- BCLI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.11% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.08%
EPS Next 2Y25.71%
EPS Next 3Y18.1%
EPS Next 5Y22.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for BCLI. In the last year negative earnings were reported.
- Also next year BCLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as BCLI's earnings are expected to grow with 18.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.71%
EPS Next 3Y18.1%
5. Dividend
5.1 Amount
- No dividends for BCLI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BRAINSTORM CELL THERAPEUTICS / BCLI FAQ
What is the ChartMill fundamental rating of BRAINSTORM CELL THERAPEUTICS (BCLI) stock?
ChartMill assigns a fundamental rating of 1 / 10 to BCLI.
Can you provide the valuation status for BRAINSTORM CELL THERAPEUTICS?
ChartMill assigns a valuation rating of 0 / 10 to BRAINSTORM CELL THERAPEUTICS (BCLI). This can be considered as Overvalued.
What is the profitability of BCLI stock?
BRAINSTORM CELL THERAPEUTICS (BCLI) has a profitability rating of 0 / 10.
Can you provide the financial health for BCLI stock?
The financial health rating of BRAINSTORM CELL THERAPEUTICS (BCLI) is 1 / 10.
What is the expected EPS growth for BRAINSTORM CELL THERAPEUTICS (BCLI) stock?
The Earnings per Share (EPS) of BRAINSTORM CELL THERAPEUTICS (BCLI) is expected to grow by 33.08% in the next year.